Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug

Detalles Bibliográficos
Autores principales: Billaud, E, Lacombe, JM, Abgrall, A, Ghosn, J, Launay, O, Livrozet, JM, Meynard, JL, Pavie, J, Costagliola, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The International AIDS Society 2010
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113097/
http://dx.doi.org/10.1186/1758-2652-13-S4-P9
_version_ 1782205887175196672
author Billaud, E
Lacombe, JM
Abgrall, A
Ghosn, J
Launay, O
Livrozet, JM
Meynard, JL
Pavie, J
Costagliola, D
author_facet Billaud, E
Lacombe, JM
Abgrall, A
Ghosn, J
Launay, O
Livrozet, JM
Meynard, JL
Pavie, J
Costagliola, D
author_sort Billaud, E
collection PubMed
description
format Online
Article
Text
id pubmed-3113097
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher The International AIDS Society
record_format MEDLINE/PubMed
spelling pubmed-31130972011-06-13 Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug Billaud, E Lacombe, JM Abgrall, A Ghosn, J Launay, O Livrozet, JM Meynard, JL Pavie, J Costagliola, D J Int AIDS Soc Poster Presentation The International AIDS Society 2010-11-08 /pmc/articles/PMC3113097/ http://dx.doi.org/10.1186/1758-2652-13-S4-P9 Text en Copyright ©2010 Costagliola et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Presentation
Billaud, E
Lacombe, JM
Abgrall, A
Ghosn, J
Launay, O
Livrozet, JM
Meynard, JL
Pavie, J
Costagliola, D
Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug
title Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug
title_full Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug
title_fullStr Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug
title_full_unstemmed Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug
title_short Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug
title_sort outcomes in antiretroviral-naive hiv-infected patients initiating therapy with tdf/ftc plus either atazanavir/r or another third recommended drug
topic Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113097/
http://dx.doi.org/10.1186/1758-2652-13-S4-P9
work_keys_str_mv AT billaude outcomesinantiretroviralnaivehivinfectedpatientsinitiatingtherapywithtdfftcpluseitheratazanavirroranotherthirdrecommendeddrug
AT lacombejm outcomesinantiretroviralnaivehivinfectedpatientsinitiatingtherapywithtdfftcpluseitheratazanavirroranotherthirdrecommendeddrug
AT abgralla outcomesinantiretroviralnaivehivinfectedpatientsinitiatingtherapywithtdfftcpluseitheratazanavirroranotherthirdrecommendeddrug
AT ghosnj outcomesinantiretroviralnaivehivinfectedpatientsinitiatingtherapywithtdfftcpluseitheratazanavirroranotherthirdrecommendeddrug
AT launayo outcomesinantiretroviralnaivehivinfectedpatientsinitiatingtherapywithtdfftcpluseitheratazanavirroranotherthirdrecommendeddrug
AT livrozetjm outcomesinantiretroviralnaivehivinfectedpatientsinitiatingtherapywithtdfftcpluseitheratazanavirroranotherthirdrecommendeddrug
AT meynardjl outcomesinantiretroviralnaivehivinfectedpatientsinitiatingtherapywithtdfftcpluseitheratazanavirroranotherthirdrecommendeddrug
AT paviej outcomesinantiretroviralnaivehivinfectedpatientsinitiatingtherapywithtdfftcpluseitheratazanavirroranotherthirdrecommendeddrug
AT costagliolad outcomesinantiretroviralnaivehivinfectedpatientsinitiatingtherapywithtdfftcpluseitheratazanavirroranotherthirdrecommendeddrug

Ejemplares similares